Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Home > ½ÃÀ庸°í¼­ > ÆÄ¸Ó½´Æ¼Äà > ½Å¾à°³¹ß > ¿ÜºÎ ¼Ò½º¸¦ ÀÌ¿ëÇÑ Á¶±â ÆÄÀÌÇÁ¶óÀÎ ±¸Ãà Àü·«
Ä«Å×°í¸®
ÆÄ¸Ó½´Æ¼Äà (4931)
°¨¿°Áúȯ (349)
°ñÁúȯ Ä¡·á (38)
´ç´¢º´ (194)
¹é½Å (181)
ºñ¸¸Ä¡·á/´ÙÀÌ¾îÆ® (44)
ºñó¹æ ÀǾàǰ (152)
¼öÀÇÇÐ (17)
½Å°æÁúȯ (174)
½Å¾à°³¹ß (1529)
¾ÏÄ¡·á (941)
¾à¹°Àü´Þ (185)
ÀǾàǰ ±ÔÁ¦È¯°æ (127)
Á¤½ÅÁúȯ (86)
Á¦³×¸¯ ÀǾàǰ (128)
Á¦¾àȸ»çºÐ¼® (523)
󹿾à (165)
½ÃÀ庸°í¼­

¿ÜºÎ ¼Ò½º¸¦ ÀÌ¿ëÇÑ Á¶±â ÆÄÀÌÇÁ¶óÀÎ ±¸Ãà Àü·«

Strategies for Building Early-Stage Pipelines Through External Sources

¸®¼­Ä¡»ç Decision Resources, Inc.
¹ßÇàÀÏ 2009³â 07¿ù »óǰÄÚµå 97067
ÆäÀÌÁö Á¤º¸ 29 Pages
°¡°Ý
US $ 3,450 £Ü 4,110,600 PDF by E-mail (Global License)


Decision Resources, Inc. ¿¡¼­ 2009³â 07¿ù ¿¡ ¹ßÇàÇÑ ¡¸¿ÜºÎ ¼Ò½º¸¦ ÀÌ¿ëÇÑ Á¶±â ÆÄÀÌÇÁ¶óÀÎ ±¸Ãà Àü·«¡¹ º¸°í¼­´Â 29 Pages·Î ±¸¼ºµÇ¾î, US $3,450 ºÎÅÍ ±¸¸Å °¡´ÉÇÕ´Ï´Ù.

Çѱ۸ñÂ÷

¾àÁ¦ °³¹ß ÆÄÀÌÇÁ¶óÀÎÀÇ Áõ°­°ú ¿¬±¸ °³¹ßÀÇ »ý»ê¼º Çâ»óÀ» À§ÇØ Á¦¾àȸ»ç´Â ¿ÜºÎ ¼Ò½º¸¦ Ȱ¿ëÇÑ Á¦Ç° °³¹ß°ú ±â¼ú Çõ½ÅÀ» ¸ð»öÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ÀÌ Á¦°øÇÏ´Â °¡Ä¡ÀÖ´Â ±â¼ú°ú Ç¥Àû, È­ÇÕ¹°À» ÀÌ¿ëÇÑ »õ·Î¿î ºñÁî´Ï½º ¸ðµ¨ÀÇ °³¹ßÀ» ÅëÇØ °æÇÕ¼ºÀ» ³ôÀÌ·Á Çϰí ÀÖ½À´Ï´Ù.

Á¶±â ÆÄÀÌÇÁ¶óÀÎ ±¸ÃàÀÇ Çʿ伺°ú ±×°ÍÀ» À§ÇÑ Á¦ÈÞ Àü·«, ÁÖ¸ñ¹Þ´Â ±â¼ú°ú ¾÷°èÀÇ ÇâÈÄ Àü¸Á µî¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

    1. °³¿ä
    2. ¼­·Ð
    3. ±â¼ú Çõ½Å Á¢±Ù Àü·«
    • ÇÕº´ ¹× ¸Å¼ö
    • ±â¾÷°£ Á¦ÈÞ
    • Çмú±â°ü°úÀÇ Çù·Â
    4. Á¦ÈÞ¸¦ ÅëÇÑ Á¶±â ÆÄÀÌÇÁ¶óÀÎ ±¸Ãà Àü·«
    • »õ·Î¿î Ç¥Àû
    • ±â¼ú Ç÷§Æû
    5. ÁÖ¸ñÇØ¾ß ÇÒ °Å·¡ µ¿Çâ
    • Genentech/Bayhill Therapeutics
    • Boehringer Ingelheim/Vitae Pahrmaceuticals
    • GlaxosmithKline/Concert Pharmaceuticals
    • Sanofi-Aventis/Exelixis
    • Wyeth/Santaris Pharma
    • Alnylam/Takeda
    • Merck/GlycoFi
    6. ¾÷°èÀÇ ÇâÈÄ Àü¸Á
    7. µµÇ¥
LSH
Back to Top